Comparative Pharmacology
Head-to-head clinical analysis: MOLINDONE HYDROCHLORIDE versus PROLIXIN ENANTHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOLINDONE HYDROCHLORIDE versus PROLIXIN ENANTHATE.
MOLINDONE HYDROCHLORIDE vs PROLIXIN ENANTHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist; also blocks serotonin 5-HT2A receptors and alpha-adrenergic receptors.
Fluphenazine (the active entity of PROLIXIN ENANTHATE) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic and mesocortical pathways. It also exhibits alpha-adrenergic blocking and anticholinergic effects.
50-225 mg/day orally in 3-4 divided doses; usual effective dose 50-75 mg/day; maximum 225 mg/day.
12.5-50 mg intramuscularly every 1-3 weeks. Initial dose: 2.5-12.5 mg IM as a test dose; gradual titration based on response and tolerability.
None Documented
None Documented
1.5-2 hours; shorter than typical antipsychotics, requiring multiple daily dosing.
Terminal elimination half-life approximately 11-15 days due to slow release from intramuscular depot; requires monitoring for prolonged effects after discontinuation
Renal: 65-70% as metabolites and unchanged drug; Fecal: 20-25%; Biliary: minor.
Primarily renal (30-40% as metabolites, <1% unchanged) and biliary/fecal (15-20%)
Category C
Category C
Antipsychotic
Antipsychotic